{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:27:20Z","timestamp":1774682840231,"version":"3.50.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,7,15]]},"DOI":"10.2169\/internalmedicine.0647-22","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:41:14Z","timestamp":1669790474000},"page":"2103-2105","source":"Crossref","is-referenced-by-count":8,"title":["Fanconi Syndrome Associated with Long-term Treatment with Zoledronate"],"prefix":"10.2169","volume":"62","author":[{"given":"Rinko","family":"Katsunuma","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Mitsumoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakauchi","sequence":"additional","affiliation":[{"name":"Department of Brest Surgery, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uzu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nippon Life Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. World Health Organization. Breast cancer [Internet]. [cited 2021 Mar 26]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89: 363-368, 2020.","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32: 1475-1495, 2021.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"4","unstructured":"4. Gradishar WJ, Anderson BO, Agraham J, et al. Breast cancer, ver 3.2020, NCCN clinical practice guideline in oncology. J Natl Compr Canc Netw 18: 452-478, 2020."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Coleman R, Camreon D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol 15: 997-1006, 2014.","DOI":"10.1016\/S1470-2045(14)70302-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Roth KS, Foreman JW, Segal S. The Fanconi syndrome and mechanisms of tubular transport dysfunction. Kidney Int 20: 705-716, 1981.","DOI":"10.1038\/ki.1981.200"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 4: 1275-1283, 2009.","DOI":"10.2215\/CJN.02050309"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM 107: 261-269, 2014.","DOI":"10.1093\/qjmed\/hct258"},{"key":"9","unstructured":"9. Fadia M, Puri P, Jiang S, Wajih Z. Letrozole-induced acute interstitial nephritis. J Clin Med Case Rep 2020-1-106."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Major P, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88: 6-14, 2000.","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 74: 1385-1393, 2008.","DOI":"10.1038\/ki.2008.356"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yoshinami T, Yagi T, Sakai D, Sugimoto N, Imamura F. A case of acquired Fanconi syndrome induced by zoledronic acid. Intern Med 50: 1075-1079, 2011.","DOI":"10.2169\/internalmedicine.50.4855"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Portales-Castillo I, Mount DB, Nigwekar SU, Yu EW, Rennke HG, Gupta S. Zoledronic acid-associated fanconi syndrome in patients with cancer. Am J Kidney Dis 80: 555-559, 2022.","DOI":"10.1053\/j.ajkd.2021.12.015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Torimoto K, Okada Y, Arao T, Mori H, Tanaka Y. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J 59: 1051-1056, 2012.","DOI":"10.1507\/endocrj.EJ12-0166"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Brewer JR, Mazot P, Soriano P. Genetic insights into the mechanisms of FGF signaling. Genes Dev 30: 751-771, 2016.","DOI":"10.1101\/gad.277137.115"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagata Y, Imanishi Y, Ishii A, et al. Evaluation of bone markers in hypophosphatemic rickets\/osteomalacia. Endocrine 40: 315-317, 2011.","DOI":"10.1007\/s12020-011-9512-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747, 2012.","DOI":"10.1038\/ki.2012.176"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fukumoto S, Soen S, Taguchi T, et al. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38: 141-144, 2020.","DOI":"10.1007\/s00774-020-01087-0"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/14\/62_0647-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T03:22:05Z","timestamp":1689391325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/14\/62_0647-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":18,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0647-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"article-number":"0647-22"}}